Overview
Updated 14 Jul 2026
Ajai Chari, MD, is Clinical Professor of Medicine at University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, Division of Hematology/Oncology. The public record shows 487 publications with 14,361 citations (h-index 51), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 29 companies.
- Most recent indexed publication: 2025 · Nature genetics
- Top research focus: Multiple Myeloma Research and Treatments
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 29 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 181.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Delayed Toxicities Post-CAR-T
Sponsor: Icahn School of Medicine at Mount Sinai
InvestigatorNot, yet, recruitingNCT07665307 - Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Sponsor: Ajai Chari
InvestigatorPhase 1/PHASE2TerminatedNCT03492138 - Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Sponsor: Icahn School of Medicine at Mount Sinai
InvestigatorPhase 2TerminatedNCT02943473
Industry payments
Updated 14 Jul 2026
29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20254 payments$22,079openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year202524 payments$15,854openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Jul 2026
102 congress contributions (2012–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Impact of low disease burden on the safety and efficacy of BCMA CAR-T in patients with Relapsed/Refractory multiple myeloma
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.
Blood cancer discovery
2024
Most-cited worksby citation count (OpenAlex)
- 01Teclistamab in Relapsed or Refractory Multiple Myeloma1,130 citations2022
- 02
- 03
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
400 Parnassus Avenue, Floor 4, San Francisco, CA 94143
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- Internal Medicine Residency
New York Presbyterian Hospital/Columbia University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
- Board Certified
Hematology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Editorial & leadership rolesjournal and society appointments
- Director
Multiple Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Principal Investigator
investigator-initiated and national/international industry-sponsored multiple myeloma clinical trials
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Secondary affiliationsappointments beyond the home institution
- 600 16th Street
#N472C, San Francisco, CA 94158 (UCSF Profiles office listing, Mission Bay campus)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/ajai-chari-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Ajai-Chari-15570763
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/AjaiChari
Mentions by otherswhere others cite or feature them
- X / Twitter
X (Twitter): @AjaiChari
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Marcus, MD
University of California, San Francisco
- 1,024
- publications
- 107
- h-index
- 16
- trials
Eric Small, MD
University of California, San Francisco
- 1,319
- publications
- 119
- h-index
- 13
- trials
Monica Gandhi, MD
University of California, San Francisco
- 462
- publications
- 66
- h-index
- 5
- trials
Charalambos Andreadis, MD
University of California, San Francisco
- 304
- publications
- 43
- h-index
- 7
- trials